other material
confidence high
sentiment positive
materiality 0.70
BioCardia CardiAMP CMI trial: +179 sec exercise tolerance, 82% fewer angina episodes at EuroPCR
BioCardia, Inc.
- Open-label cohort results presented at EuroPCR; no treatment-emergent major adverse cardiac events.
- Exercise tolerance improved by avg 179 seconds, sustained over 2-year follow-up.
- Angina episodes reduced by avg 82% by 6 months after treatment.
- All patients had refractory angina despite guideline-directed medical therapy and prior revascularization.
- Data support continued clinical development of autologous cell therapy for chronic myocardial ischemia.